Compare BOLD & HHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOLD | HHS |
|---|---|---|
| Founded | 2018 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Advertising |
| Sector | | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.7M | 21.2M |
| IPO Year | 2024 | 1994 |
| Metric | BOLD | HHS |
|---|---|---|
| Price | $1.12 | $2.78 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 63.7K | 1.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.47 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $185,242,000.00 |
| Revenue This Year | N/A | $6.54 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.96 | $2.33 |
| 52 Week High | $1.78 | $5.39 |
| Indicator | BOLD | HHS |
|---|---|---|
| Relative Strength Index (RSI) | 39.80 | 44.65 |
| Support Level | $1.10 | $2.33 |
| Resistance Level | $1.20 | $3.03 |
| Average True Range (ATR) | 0.03 | 0.08 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 26.93 |
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.